Imperial College London

King's School Bruton

Senior Associate at Evaluate Ltd

Norgine

Commercial Evaluation Manager

• Forecasted UK revenues for a top-selling biologic drug facing branded and biosimilar competition. Surveyed UK KOLs and payers to derive insights and determine parameters for revenue forecast model. Presented findings during on-site F2F meeting with client.
• Conducted due diligence for a pharmaceutical company in Asia which was seeking to acquire an investigational monoclonal antibody for oncology indications. Led the project team and built the bottom-up forecast model from scratch. Forecasted significantly lower revenues than consensus which led the client to rethink their offer.
• Undertook primary research with KOLs in N America and Europe to validate/support the value proposition/positioning of a novel imaging/diagnostics technology for prostate cancer. Led the project team and developed a patient-based revenue forecast incorporating primary research insights.

Evaluate Ltd

Senior Consultant

Project managed end-to-end GTM efforts for new products (e.g., Evaluate Analyzer and FinOptica) and enhancements to existing products (e.g., Evaluate Pharma and Omnium). Highlights:

• Hosted regular planning, alignment, and review sessions with product teams (e.g., R&D, Product Management, Software) and GTM teams (e.g., Marketing, Sales Enablement, Customer Success).
• Updated Evaluate’s end-to-end GTM process using stakeholder feedback (e.g., stage-gate requirements, GTM tiering, and required documentation).
• Used a range of project management tools (e.g., MS Project, Teams, SharePoint, Jira, Confluence).
• Exposure to agile and waterfall project management approaches.

Senior Commercial Project Manager

Managed a key workstream in an asset due diligence project for a major life sciences investor. Highlights:

• Secondary research to elucidate current and potential future treatment pathways.
• Peak patient share estimation focusing on key product/indication characteristics.
• Analogue assessment to determine likely adoption rates and price potential for R&D assets.
• Forecast model development combining bottom-up and top-down approaches.
• Report development and final presentation to client. Directed and oversaw the work of associates.

Managed a commercial assessment of a pipeline CAR-T asset in several haemato-oncology indications and multiple treatment lines for a global biotechnology company. Highlights:

• Market access and competitive assessment to understand the landscape in major markets.
• Analysis of sales, pricing, and clinical data to infer patient shares and uptake across treatment lines.
• Development of a bottom-up sales forecast with scenario and sensitivity analyses.
• Project extension to produce an rNPV-based valuation tool with additional markets.
• Gave multiple client presentations. Oversaw associates. Won repeat business.

Senior Associate

• Conducted an opportunity assessment for an AI-based medical device which was being developed to provide decision support during colonoscopy. Conducted interviews in the US and Europe, managed the project team (oversaw/directed analyst work), and generated follow-on work.
• Interviewed affiliates at a multinational pharmaceutical company to assess US and European implementation of a strategy for a biologic treatment with global sales above $1 billion.

Ipsos

• Pitched the services of ICON Pricing & Market Access Consulting to a global pharmaceutical company as part of a multi-million EUR biosimilar development deal.
• Used R to predict the launch of novel biosimilars in the US, EU5, and Japan. This involved designing complex queries for an online PostgreSQL clinical trial database and analysing the retrieved data alongside regulatory and patent information.
• Provided strategic recommendations to a global pharmaceutical company which was contemplating undertaking a rapid relative effectiveness assessment with EUnetHTA.
• Published a white paper entitled 'Making Sense of the Biosimilars: Market Strategies and Recommendations to Achieve Optimal Market Access'.
• Wrote a manuscript describing cost-effectiveness modelling for neuropathic pain treatments (https://doi.org/10.1080/13696998.2018.1486845; not listed as author).
• Won high-value projects through development of proposals.

ICON plc

Consultant

• Hosted live webinars covering the U.S. launch of Zarxio, payer insights relating to biosimilars, and expectations for rituximab biosimilars.
• Wrote reports detailing biosimilar use in oncology and immunology, access and reimbursement in key markets, and performance of Zarxio, Inflectra/Remsima and Benepali.
• Forecasted 2015-2025 sales for immune biologics (originators and biosimilars).
• Used R and Python to improve management of a biosimilar pipeline database, and Excel to analyse large quantities of US formulary data.

Decision Resources Group

Business Insights Analyst - Biosimilars Advisory Service

• Developed a pricing model to calculate strategically-favourable prices (retail, pharmacy, wholesale, EFP, and ASP) for Bemfola (a biosimilar infertility treatment) in EU markets.
• Submitted pricing applications in the UK and the Nordics, and supported applications in Germany, Spain and the Republic of Ireland.
• Wrote manuscripts describing a cost-effectiveness analysis for Eribulin in Spain and a Danish study of non-severe hypoglycaemia (doi: 10.2217/dmt.14.54; not listed as author).

Adelphi Values

Value Analyst

The Esprit Group

Booking Assistant

• Laboratory project investigating profen metabolism.
• Two resulting publications: doi: 10.1016/j.bcp.2013.08.067 and doi: 10.1039/c1cc10763a.

Tom Hutchings